Patents by Inventor Michael Philip Mazanetz
Michael Philip Mazanetz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230352114Abstract: The present invention relates generally to methods for selecting or designing a compound for modulating the aggregation of a Tau protein. The method comprising using computer-implemented molecular modelling means to compare the three-dimensional structure of a candidate compound with a three-dimensional structure of at least a part of the Tau protein comprising amino acids 315-378 and determine whether the candidate compound is able to simultaneously form non-covalent interactions with two or more of Leu315, Ser341, Glu342, Lys343, Phe346, Lys347, Val350, Ser352, Ile354, Lys369, Ile371, Glu372, Phe378 and Thr373. A candidate compound that is able to form said interactions is predicted to modulate the aggregation of the Tau protein or truncated form thereof.Type: ApplicationFiled: July 6, 2021Publication date: November 2, 2023Applicant: GTInvent LimitedInventors: Michael Philip Mazanetz, Claude Michel Wischik, Louise Charlotte Serpell, John Mervyn David Storey
-
Publication number: 20230165875Abstract: The present invention provides methods of treating COVID-19 in a subject using methylthioninium compounds.Type: ApplicationFiled: April 30, 2021Publication date: June 1, 2023Applicant: WisTa Laboratories Ltd.Inventors: Claude Michel Wischik, Mohammad Arastoo, Michael Philip Mazanetz
-
Publication number: 20230165876Abstract: T he present invention provides methods of treating COV-ID-19 in a subject using methylthioninium compounds.Type: ApplicationFiled: April 30, 2021Publication date: June 1, 2023Applicant: WisTa Laboratories Ltd.Inventors: Claude Michel Wischik, Mohammad Arastoo, Michael Philip Mazanetz
-
Publication number: 20230158040Abstract: The present invention provides methods of alleviating hypoxemia in a subject through oral administration of a methylthioninium compound.Type: ApplicationFiled: April 30, 2021Publication date: May 25, 2023Applicant: WisTa Laboratories Ltd.Inventors: Claude Michel Wischik, Mohammad Arastoo, Michael Philip Mazanetz
-
Patent number: 9187478Abstract: The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among —O—R3 or —NR3R4, R3 is C1-6-alkyl which is substituted by R5 and R6, R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, —C1-6-alkylen-O—C1-3-alkyl, C1-3-haloalkyl, R6 is ring X wherein n is either 0 or 1, and is a either a single or a double bond and wherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, —C1-3-alkyl, —C1-3-haloalkyl, —O—C1-3-alkyl, —C1-3-alkanol and halogen, and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well aType: GrantFiled: January 8, 2015Date of Patent: November 17, 2015Assignee: Boehringer Ingellheim International GmbHInventors: Matthias Hoffmann, Georg Dahmann, Dennis Fiegen, Sandra Handschuh, Jasna Klicic, Guenter Linz, Gerhard Schaenzle, Andreas Schnapp, Stephen Peter East, Michael Philip Mazanetz, Robert John Scott, Edward Walker
-
Publication number: 20150126503Abstract: The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among —O—R3 or —NR3R4, R3 is C1-6-alkyl which is substituted by R5 and R6, R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, —C1-6-alkylen-O—C1-3-alkyl, C1-3-haloalkyl, R6 is ring X wherein n is either 0 or 1, and is a either a single or a double bond and wherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, —C1-3-alkyl, —C1-3-haloalkyl, —O—C1-3-alkyl, —C1-3-alkanol and halogen, and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well as phaType: ApplicationFiled: January 8, 2015Publication date: May 7, 2015Inventors: Matthias HOFFMANN, Georg DAHMANN, Dennis FIEGEN, Sandra HANDSCHUH, Jasna KLICIC, Guenter LINZ, Gerhard SCHAENZLE, Andreas SCHNAPP, Stephen Peter EAST, Michael Philip MAZANETZ, Robert John SCOTT, Edward Walker
-
Patent number: 8969568Abstract: The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among —O—R3 or —NR3R4, R3 is C1-6-alkyl which is substituted by R5 and R6, R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, —C1-6-alkylen-O—C1-3-alkyl, C1-3-haloalkyl, R6 is ring X wherein n is either 0 or 1, and is a either a single or a double bond and wherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, —C1-3-alkyl, —C1-3-haloalkyl, —O—C1-3-alkyl, —C1-3-alkanol and halogen, and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as welType: GrantFiled: January 26, 2011Date of Patent: March 3, 2015Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Matthias Hoffmann, Georg Dahmann, Dennis Fiegen, Sandra Handschuh, Jasna Klicic, Guenter Linz, Gerhard Schaenzle, Andreas Schnapp, Stephen Peter East, Michael Philip Mazanetz, Robert John Scott, Edward Walker
-
Patent number: 8680091Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.Type: GrantFiled: June 9, 2011Date of Patent: March 25, 2014Assignee: Eli Lilly and CompanyInventors: Karen Briner, Manuel Javier Cases-Thomas, Marta Adeva Bartolome, Christopher Stanley Galka, Alicia Marcos Llorente, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, John Cunningham O'Toole, Richard Edmund Rathmell, Matthew Robert Reinhard, Selma Sapmaz, Andrew Caerwyn Williams
-
Patent number: 8420631Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where R6 is —C?C—R10, —CH?CR11R11?, or —(C0-C8)alkyl-Ar2 optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents and other substituents are as defined in the specification.Type: GrantFiled: September 1, 2006Date of Patent: April 16, 2013Assignee: Eli Lilly and CompanyInventors: John Gordon Allen, Karin Briner, Anne Marie Camp, Manuel Javier Cases-Thomas, Richard Charles Hoying, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, Natalia Pokrovskaia, Richard Edmund Rathmell, Roger Ryan Rothhaar, Selma Sapmaz, Andrew Caerwyn Williams
-
Patent number: 8202873Abstract: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently —C(H)? or —N?, provided that at least one of A and B is —N?, n is 1-3, m is 0-3, and R1-4 are as defined herein.Type: GrantFiled: May 7, 2008Date of Patent: June 19, 2012Assignee: Eli Lilly and CompanyInventors: Valentina O. Badescu, Anne Marie Camp, Barry Peter Clark, Michael Philip Cohen, Sandra Ann Filla, Peter Thaddeus Gallagher, Sarah Lynne Hellman, Michael Philip Mazanetz, Marta Maria Pineiro-Nunez, John Mehnert Schaus, Patrick Gianpietro Spinazze, Maria Ann Whatton
-
Publication number: 20120028939Abstract: The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among —O—R3 or —NR3R4, R3 is C1-6-alkyl which is substituted by R5 and R6, R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, —C1-6-alkylen-O—C1-3-alkyl, C1-3-haloalkyl, R6 is ring X wherein n is either 0 or 1, and is a either a single or a double bond and wherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, —C1-3-alkyl, —C1-3-haloalkyl, —O—C1-3-alkyl, —C1-3-alkanol and halogen, and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as welType: ApplicationFiled: January 26, 2011Publication date: February 2, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Matthias Hoffmann, Georg Hoffmann, Dennis Fiegen, Sandra Handschuh, Jasna Klicic, Guenter Linz, Gerhard Schaenzle, Andreas Schnapp, Stephen Peter East, Michael Philip Mazanetz, Robert John Scott, Edward Walker
-
Publication number: 20120028961Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.Type: ApplicationFiled: July 28, 2011Publication date: February 2, 2012Applicant: ELI LILLY AND COMPANYInventors: JOHN GORDON ALLEN, Karin Briner, Michael Philip Cohen, Christopher Stanley Galka, Sarah Lynne Hellman, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothhaar, Michael Wade Tidwell, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang, Steven Armen Boyd, Richard Gerard Conway, Arundhati S. Deo, Wai-Man Lee, Christopher Stephen Siedem, Ajay Singh, Michael Philip MAZANETZ
-
Publication number: 20110269745Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.Type: ApplicationFiled: June 9, 2011Publication date: November 3, 2011Applicant: ELI LILLY AND COMPANYInventors: Karin BRINER, Marta ADEVA BARTOLOME, Manuel Javier CASES-THOMAS, Christopher Stanley GALKA, Alicia MARCOS LLORENTE, Maria Angeles MARTINEZ-GRAU, Michael Philip MAZANETZ, John Cunningham O'Toole, Richard Edmund RATHMELL, Matthew Robert REINHARD, Selma SAPMAZ, Andrew Caerwyn WILLIAMS
-
Patent number: 8022062Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —C?C—R10, —O—R12, —S—R14, or —NR24R25; and other substituents are as defined in the specification.Type: GrantFiled: February 18, 2005Date of Patent: September 20, 2011Assignee: Eli Lilly and CompanyInventors: John Gordon Allen, Karin Briner, Michael Philip Cohen, Christopher Stanley Galka, Sarah Lynne Hellman, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothhaar, Michael Wade Tidwell, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang, Michael Philip Mazanetz
-
Patent number: 7981882Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.Type: GrantFiled: September 1, 2006Date of Patent: July 19, 2011Assignee: Eli Lilly and CompanyInventors: Karin Briner, Anne Marie Camp, Alan Cornell, Michael Philip Mazanetz, Roger Ryan Rothhaar, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang
-
Publication number: 20100120785Abstract: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently C(H)? or N?, provided that at least one of A and B is —N?, n is 1-3, m is 0-3, and R14 are as defined herein.Type: ApplicationFiled: May 7, 2008Publication date: May 13, 2010Applicant: ELI LILLY AND COMPANYInventors: Valentina O. Badescu, Anne Marie Camp, Barry Peter Clark, Michael Philip Cohen, Sandra Ann Filla, Peter Thaddeus Gallagher, Sarah Lynne Hellman, Michael Philip Mazanetz, Marta Maria Pineiro-Nunez, John Mehnert Schaus, Patrick Gianpietro Spinazze, Maria Ann Whatton
-
Publication number: 20090099155Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzoazepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is -C?C-R10, -O-R12, -S-R14, or -NR24R25; and other substituents are as defined in the specification.Type: ApplicationFiled: September 9, 2005Publication date: April 16, 2009Inventors: John Gordon Allen, Karin Briner, Michael Philip Cohen, Christopher Stanley Galka, Sarah Lynne Hellman, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothaar, Michael Wade Tidwell, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang, Steven Armen Boyd, Richard Gerard Conway, Arundhati S. Deo, Wai-Man Lee, Christopher Stephen Siedem, Ajay Singh, Michael Philip Mazanetz
-
Publication number: 20080269196Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.Type: ApplicationFiled: September 1, 2006Publication date: October 30, 2008Inventors: Karin Briner, Maria Adeva Bartolome, Manuel Javier Cases-Thomas, Christopher Stanley Galka, Alicia Marcos Llorente, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, John Cunningham O' Toole, Richard Edmund Rathmell, Matthew Robert Reinhard, Selma Sapmaz, Andrew Caerwyn Williams
-
Publication number: 20080214520Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.Type: ApplicationFiled: September 1, 2006Publication date: September 4, 2008Inventors: Karin Briner, Anne Marie Camp, Alan Cornell, Michael Philip Mazanetz, Roger Ryan Rothhaar, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang
-
Publication number: 20080207897Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where R6 is —C?C—R10, —CH?CR11R11?, or —(C0-C8)alkyl-Ar2 optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents and other substituents are as defined in the specification.Type: ApplicationFiled: September 1, 2006Publication date: August 28, 2008Inventors: John Gordon Allen, Karin Briner, Anne Marie Camp, Manuel Javier Cases-Thomas, Richard Charles Hoying, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, Natalia Pokrovskaia, Richard Edmund Rathmell, Roger Ryan Rothhaar, Selma Sapmaz, Andrew Caerwyn Williams